Hereditary Angioedema Market, By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI4218 | Publish Date: May 2023 | No. of Pages: 160

Global Hereditary Angioedema Market By Overview

Hereditary angioedema (HAE) is a rare disorder characterized by recurrent episodes of severe swelling (angioedema). Patient with HAE symptoms include edema (swelling) in various parts of the body, majorly at hands, feet, face, and throat. HAE symptoms typically initiate in childhood which then worsen during puberty. Majorly there are three types of hereditary angioedema, named as type I, II, and III which are distinguished on the basis of underlying causes and levels of a protein called C1 inhibitor in the patient’s blood. There are three main sorts of HAE. Types I and II are caused by a mutation within the SERPING1 gene, which makes the C1 inhibitor protein, while type III is usually thanks to a mutation within the F12 (factor XII) gene. The result's increased levels of bradykinin, which promotes swelling. The condition could also be inherited from an individual's parents in an autosomal dominant manner or occur as a replacement mutation. Triggers for an attack may include minor trauma or stress, but attacks often occur with none obvious preceding event. Diagnosis of types I and II is predicated on measurement of C4 and C1-inhibitor levels. Management of HAE involves efforts to stop attacks and therefore the treatment of attacks if they occur. During an attack, supportive care like intravenous fluids and airway support could also be required.C1 inhibitor medications are often used for both prevention and treatment, while ecallantide and icatibant are often wont to treat acute attacks. The Global Hereditary Angioedema Market accounted for US$ 2.72 billion in 2020 and is estimated to be US$ 6.35 billion by 2030 and is anticipated to register a CAGR of 8.4%.

Global Hereditary Angioedema Market By Dynamics

                                                    

Growing research and development activities

Growing research and development activities by key players in this market, coupled with increased support by various government and healthcare regulatory bodies operating in treatment of hereditary angioedema are major factors driving growth of the market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved CSL Behring’s Haegarda (C1-esterase inhibitor), which is indicated for routine prophylaxis to prevent hereditary angioedema attacks in adolescent and adult patients. In September 2018, Health Canadahas authorizedShire plc’s TAKHZYRO (lanadelumab injection) for prevention of hereditary angioedema (HAE) attacks in adolescents and adults 12 years of age and older.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Hereditary Angioedema Market By Segmentation

                                                     

The global hereditary angioedema market has been segmented on the basis of drug class, route of administration, distribution channel, and region.

On the basis of drug class, hereditary angioedema market is segmented into C1 esterase inhibitor, kallikrein inhibitor, bradykinin receptor, attenuated androgens, and others. On the basis of route of administration, target market is segmented into subcutaneous, intravenous, and oral. Moreover, on the basis of distribution channel, hereditary angioedema market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Furthermore, on the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Regional Insights:

                                     

For detailed understanding of market dynamics,on the basis of region, the target market is sun segmented into North America, Asia Pacific, Europe, Latin America and Middle East & Africa. North America dominates the hereditary angioedema therapeutic market due to the new product launches by major players. Asia-Pacific is projected to observe significant amount of growth in the hereditary angioedema therapeutic market due to the rise in the patient awareness levels.

                                             

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Drug Class: C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others By Route of Administration: Subcutaneous, Intravenous, and Oral

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Global Hereditary Angioedema Market, By Drug Class:

  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others

Global Hereditary Angioedema Market, By Route of Administration:

  • Subcutaneous
  • Intravenous
  • Oral

Global Hereditary Angioedema Market, By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Global Hereditary Angioedema Market, By Region:

      • North America
        • North America Hereditary Angioedema Market, By Drug Class
        • North America Hereditary Angioedema Market, By Route of Administration
        • North America Hereditary Angioedema Market, By Distribution Channel
        • North America Hereditary Angioedema Market, By Country
          • The U.S.
          • Canada
      • Europe
        • Europe Hereditary Angioedema Market, By Drug Class
        • Europe Hereditary Angioedema Market, By Route of Administration
        • Europe Hereditary Angioedema Market, By Distribution Channel
        • Europe Hereditary Angioedema Market, By Country
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
        • Asia Pacific Hereditary Angioedema Market, By Drug Class
        • Asia Pacific Hereditary Angioedema Market, By Route of Administration
        • Asia Pacific Hereditary Angioedema Market, By Distribution Channel
        • Asia Pacific Hereditary Angioedema Market, By Country
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
        • Latin America Hereditary Angioedema Market, By Drug Class
        • Latin America Hereditary Angioedema Market, By Route of Administration
        • Latin America Hereditary Angioedema Market, By Distribution Channel
        • Latin America Hereditary Angioedema Market, By Country
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
        • Middle East & Africa Hereditary Angioedema Market, By Drug Class
        • Middle East & Africa Hereditary Angioedema Market, By Route of Administration
        • Middle East & Africa Hereditary Angioedema Market, By Distribution Channel
        • Middle East & Africa Hereditary Angioedema Market, By Country
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Hereditary Angioedema Market By Key Players

                                                                                

Key players operating in the global hereditary angioedema market includes CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Attune Pharmaceuticals, Inc.

Global Hereditary Angioedema Market By Company Profile

      • CSL Behring
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Shire Plc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Pharming Healthcare
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • BioCryst Pharmaceuticals, Inc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Ionis Pharmaceuticals, Inc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Arrowhead Pharmaceuticals
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Adverum Biotechnologies
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Attune Pharmaceuticals, Inc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance

Global Hereditary Angioedema Market By Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Hereditary Angioedema Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Hereditary Angioedema Market , By Drug Class,  2020 – 2030, (US$ Mn)
    • Overview                          
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • C1 Esterase Inhibitor
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Kallikrein Inhibitor
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Bradykinin Receptor
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Attenuated Androgens
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Hereditary Angioedema Market , By Route of Administration,  2020 – 2030, (US$ Mn)
    • Overview                
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Subcutaneous
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Intravenous
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Oral
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Hereditary Angioedema Market , By Distribution Channel, 2020 – 2030, (US$ Mn)
    • Overview                   
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Hereditary Angioedema Market , By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Drug Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Route of Administration, Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
      • CSL Behring
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Shire Plc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Pharming Healthcare
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • BioCryst Pharmaceuticals, Inc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Ionis Pharmaceuticals, Inc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Arrowhead Pharmaceuticals
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Adverum Biotechnologies
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance
      • Attune Pharmaceuticals, Inc.
          • Company Overview
          • Product Portfolio
          • Key Highlights
          • Financial Performance

The Last Word

    • Future Impact
    • About Us
    • Contact

FAQs

The global hereditary angioedema market has been segmented on the basis of drug class, route of administration, distribution channel, and region.

Growing research and development activities by key players in this market, coupled with increased support by various government and healthcare regulatory bodies operating in treatment of hereditary angioedema are major factors driving growth of the market.

North America dominates the market of global Hereditary Angioedema over forecast period.

Key players operating in the global hereditary angioedema market includes CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Attune Pharmaceuticals, Inc.